Research map: Dose Optimization and the Implementation of Project Optimus

Back to the article

Papers in this map

  1. Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development · Jayakrishna Ambati · 2020 · 66 citations · Cited by this paper
  2. Acupuncture in Cancer Care: Evidence, Safety, and Implementation in Oncology Practice · 2026 · Related
  3. Economic Analyses of Phase III Cooperative Cancer Group Clinical Trials: Are They Feasible? · Charles Lee Bennett · 1997 · 42 citations · Cited by this paper
  4. Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis · 2026 · Related
  5. A 56-Year-Old Physician Who Underwent a PSA Test · Charles Lee Bennett · 2012 · 33 citations · Cited by this paper
  6. Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid Tumors · 2026 · Related
  7. The Retrofit: Lessons From Sotorasib's Dosing Conundrum · Harpreet Singh · 2024 · 13 citations · Cited by this paper
  8. Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021 · 2026 · Related
  9. Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met? · Sanjay Popat · 2024 · 11 citations · Cited by this paper
  10. When Systems Fail the Vulnerable: Cancer Care for Patients With Mental Illness · 2026 · Related
  11. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? · Mark J. Ratain · 2023 · 5 citations · Cited by this paper
  12. Implementing Systems-Based Interventions to Improve the Care of Cancer Survivors: Small Steps, Large Challenges · 2026 · Related
  13. Missed Opportunity for Sotorasib Dose Optimization · Garth William Strohbehn · 2025 · 1 citation · Cited by this paper
  14. Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials · 2026 · Related
  15. Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery · 2026 · Related
  16. Participation Is Not Reform: Why 340B Discounts Should Follow the Patient · 2026 · Related
  17. Adoption of Bevacizumab Biosimilars in Medicare Part B: Socioeconomic and Geographic Variation, 2019–2023 · 2026 · Related

Source: OpenAlex (CC0)